AstraZeneca Pharma India Limited — Others, 24-02-2025: Shareholders meeting

AstraZeneca Pharma India Limited has announced a board meeting to conduct a postal ballot seeking members' approval for material related party transactions with AstraZeneca UK Limited and AstraZeneca AB, Sweden. The proposed transactions are valued at a maximum of ₹2,100 crore and ₹800 crore, respectively, covering the period from April 1, 2025, to March 31, 2026. This move is essential for maintaining operational efficiency and meeting business growth demands. Investors may view this as a positive outlook, as it signifies ongoing relationships with key partners to ensure product availability and support company operations.